3 results
Using a single formulation of PfPEBS LSP administered at two different doses, one of 5*g and the other one of 30*g, both adjuvanted with aluminium hydroxide, in two immunizations at 28 days interval, to evaluate a) the safety and immunogenicity (…
Primary: To demonstrate the superiority of secukinumab 150 mg and/or 300 mg to placebo in subjects with moderate to severe palmoplantar psoriasis as assessed by the palmoplantar Investigator*s Global Assessment (ppIGA) at Week 16.Secondary: Efficacy…
The purpose of the study is to investigate the use of secukinumab (AIN457) treat ment in children from 2 to18 years of age with either active Enthesitis -Related Arthritis (ERA) or Juvenile Psoriatic Arthritis (JPsA) subtypes of Juvenile Idiopathic…